Treatment and molecular analysis of bullous pemphigoid with tofacitinib: a case report and review of current literature.

ABSTRACT:

Background

Bullous pemphigoid (BP) is a rare, life-threatening autoimmune blistering disease with pruritus and tension blisters/bullous as the main clinical manifestations. Glucocorticosteroids are the main therapeutic agents for it, but their efficacy is poor in some patients. Tofacitinib, a small molecule agent that inhibits JAK1/3, has shown incredible efficacy in a wide range of autoimmune diseases and maybe a new valuable treatment option for refractory BP.

Objective

To report a case of refractory BP successfully treated with tofacitinib, then explore the underlying mechanism behind the treatment, and finally review similarities to other cases reported in the literature.

Methods

Case report and literature review of published cases of successful BP treatment with

SUBMITTER: Li X 

PROVIDER: S-EPMC11532171 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature